Participants 136 191 5
stroke prevention in patients with atrial fibrillation.
Participants 312 363 4
patients with non-valvular atrial fibrillation (AF)
Participants 398 571 7
multicentre, multinational study, 1,146 patients with AF and risk of stroke were randomised to edoxaban 30 mg qd, 30 mg bid, 60 mg qd, or 60 mg bid or warfarin dose-adjusted
Participants 835 894 4
Mean age was 65 +/- 8.7 years and 64.4% were warfarin-na√Øv
